Schechter Investment Advisors LLC Takes Position in Translational Development Acquisition Corp. (NASDAQ:TDACU)

Schechter Investment Advisors LLC purchased a new stake in shares of Translational Development Acquisition Corp. (NASDAQ:TDACUFree Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 150,640 shares of the company’s stock, valued at approximately $2,778,000.

Other large investors have also recently modified their holdings of the company. Tuttle Capital Management LLC bought a new stake in Translational Development Acquisition during the fourth quarter valued at about $461,000. Wealthspring Capital LLC bought a new position in shares of Translational Development Acquisition during the 4th quarter worth approximately $1,095,000. Wolverine Asset Management LLC bought a new position in shares of Translational Development Acquisition during the 4th quarter worth approximately $5,716,000. MMCAP International Inc. SPC bought a new position in shares of Translational Development Acquisition during the 4th quarter worth approximately $6,454,000. Finally, Calamos Advisors LLC bought a new position in shares of Translational Development Acquisition during the 4th quarter worth approximately $6,915,000.

Translational Development Acquisition Price Performance

NASDAQ TDACU opened at $10.12 on Monday. Translational Development Acquisition Corp. has a 52 week low of $10.00 and a 52 week high of $10.30. The stock’s 50 day moving average price is $10.06.

About Translational Development Acquisition

(Free Report)

Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector.

Read More

Institutional Ownership by Quarter for Translational Development Acquisition (NASDAQ:TDACU)

Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.